NDA 211527 · Galderma Labs Lp
Aklief
Trifarotene · Topical · Retinoid
NovelLast checked: Nov 19, 2026Latest source record: Jul 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Oct 4, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
6 Phase 3, 0 recruiting
FAERS reports
183
43 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 16, 2024.
AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ( 1 )
Mechanism: Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- AKLIEF · TRIFAROTENE 0.005% · CREAM, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trifarotene" as an intervention, any sponsor and status, largest first.
- Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT02556788 · 1,212 participants · Start Nov 2015 · Primary completion Feb 7, 2017
Drug: CD5789 (trifarotene) 50µg/g Cream; Placebo Cream · For: Acne Vulgaris
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 81 sites in all
- Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT02566369 · 1,208 participants · Start Nov 30, 2015 · Primary completion Nov 14, 2017
Drug: CD5789 (trifarotene) 50μg/g cream; Placebo cream · For: Acne Vulgaris
Sites: Mobile, Alabama; Glendale, Arizona; Phoenix, Arizona · 124 sites in all
- A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT06733402 · 1,000 participants · Start Jun 20, 2024 · Primary completion Jun 20, 2024
Drug: Trifarotene Cream 0.005%; AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG and 2 more · For: Acne Vulgaris
Sites: Hawthorne, New York
- Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne VulgarisPivotal-lookingCompleted
Teva Pharmaceuticals USATeva (TEVA)
NCT05550337 · 807 participants · Start Sep 19, 2022 · Primary completion May 9, 2023
Drug: Trifarotene 0.005 % Topical Cream; AKLIEF® and 1 more · For: Acne Vulgaris
Sites: West Covina, California; Brandon, Florida; Fort Lauderdale, Florida · 14 sites in all
- A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne VulgarisPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT06063473 · 762 participants · Start Feb 22, 2023 · Primary completion Jul 13, 2023
Drug: Trifarotene Cream 0.005%; Placebo and 1 more · For: Acne Vulgaris
Sites: Hawthorne, New York
- A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne VulgarisPivotal-lookingActive, not recruiting
Galderma R&DIndustry
NCT07186413 · 561 participants (planned) · Start Sep 23, 2025 · Primary completion Dec 31, 2026
Drug: Trifarotene; Vehicle Cream · For: Acne Vulgaris
Sites: Shanghai, China
- CD5789 (Trifarotene) Long Term Safety Study on Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT02189629 · 453 participants · Start Feb 23, 2015 · Primary completion Feb 23, 2017
Drug: CD5789 (trifarotene) · For: Acne Vulgaris
Sites: Mobile, Alabama; Rogers, Arkansas; Sacramento, California · 32 sites in all
- Dose Range Study of CD5789 in Acne VulgarisPivotal-lookingCompleted
Galderma R&DIndustry
NCT01616654 · 304 participants · Start Jun 20, 2012 · Primary completion Jul 24, 2013
Drug: CD5789 25 µg/g cream; CD5789 50 µg/g cream and 3 more · For: Acne Vulgaris
Sites: Birmingham, Alabama; Glendale, California; Marina del Rey, California · 24 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- erythema28
- acne17
- skin burning sensation17
- urinary retention16
- dry skin15
- mydriasis15
- skin exfoliation14
- skin irritation13
- off label use12
- drug ineffective11
- vision blurred10
- pain of skin9
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2020 | 26 |
| 2021 | 41 |
| 2022 | 20 |
| 2023 | 42 |
| 2024 | 21 |
| 2025 | 18 |
| 2026 | 14 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aklief (Trifarotene)
2024 spending
$260K
Beneficiaries
186
373 claims
Per beneficiary
$1,395
$15.18 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $51,447 |
| 2021 | $149,786 |
| 2022 | $178,334 |
| 2023 | $197,712 |
| 2024 | $259,556 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.
Tan J, Thiboutot D, Popp G, et al. · J Am Acad Dermatol 2019 · Clinical Trial, Phase III
- Trifarotene for the Treatment of Facial and Truncal Acne.
Bell KA, Brumfiel CM, Haidari W, et al. · Ann Pharmacother 2021 · Systematic Review
- Patient Insights on Acne Hyperpigmentation, Trifarotene, and Skincare: 6-Month, LEAP Phase 4 Qualitative Exit Interview Findings.
Dias-Barbosa C, Taylor N, Chan K, et al. · Patient 2026 · Randomized Controlled Trial, Clinical Trial, Phase IV
- Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation.
Alexis A, Del Rosso JQ, Forman S, et al. · Int J Dermatol 2024 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne.
Blume-Peytavi U, Fowler J, Kemény L, et al. · J Eur Acad Dermatol Venereol 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Galderma Labs Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.